Heart rate variability after BRL37344, a beta-3 agonist, in experimental bladder outlet obstruction
Journal Title: Advances in Hygiene and Experimental Medicine - Year 2013, Vol 67, Issue 0
Abstract
Introduction: Bladder overactivity symptoms accompany benign prostatic hyperplasia (BPH) syndrome. The autonomic nervous system (ANS) disturbances may be involved in bladder dysfunction. An ameliorating effect on bladder overactivity is being assigned to the currently investigated β-3 adrenoreceptor agonists. However, little is known about the influence of β-3 agonists on ANS activity. The aim of our study was to estimate ANS activity using heart rate variability (HRV) in experimental model of bladder outlet obstruction (BOO), reflecting human BPH.Material/Methods: 30 female rats, divided into control, non-treated BOO (LLBOO), and β-3 agonist (BRL37344) BOO treated (LLBOO+β3 agonist) were studied. BOO was evoked by 5-week long partial proximal urethra ligation. Next, 20-minute resting HRV recordings were performed in each of the studied groups following i.p. administration of the vehicle (LLBOO) or BRL37344 (LLBOO+β3 agonist).Results: LLBOO rats were characterized by diminished NN range, SDNN, and rMSSD in time-domain analysis. Similarly, TP and non-normalized spectral HRV parameters were also decreased. Contrary to these findings, normalized spectral parameters were lower (nLF) and higher (nHF). The animals treated with BRL37344 demonstrated no significant differences in time--domain HRV parameters. In spectral analysis, a decrease in LF and HF, together with a fall in TP, was found. Moreover, both nLF and nHF reached almost the same values in control and β-3 agonist treated rats.Disscussion: Our data indicates that BRL37344 is an agent abolishing the autonomic imbalance in experimental BOO, which may contribute to relieving the symptoms of bladder overactivity in β-3 agonists treated participants.
Authors and Affiliations
Łukasz Dobrek, Agnieszka Baranowska, Piotr J. Thor
Keywords
Related Articles
- EP ID EP67021
- DOI -
- Views 180
- Downloads 0
Dakarbazyna jako lek przeciwczerniakowy i referencyjny dla nowych programów terapeutycznych
Czerniak jest nowotworem wywodzącym się z melanocytów, komórek pochodzenia neuroektodermalnego. Leczenie pacjentów z czerniakiem jest trudne ze względu na agresywny przebieg choroby oraz wczesne i liczne przerzuty. Podst...
Mechanizmy działania bewacyzumabu, przeciwciała monoklonalnego anty-VEGF, na komórki przewlekłej białaczki limfocytowej
Wprowadzenie: Przewlekła białaczka limfocytowa (PBL) wciąż pozostaje chorobą nieuleczalną, dlatego wysiłki skierowane na opracowanie nowych strategii leczniczych są w pełni uzasadnione. Ważnym mechanizmem rozwoju nowotwo...
Daratumumab – przełomowy lek w terapii szpiczaka plazmocytowego
Mimo znaczących postępów w leczeniu dzięki wprowadzeniu do terapii leków immunomodulujących i inhibitorów proteasomu, szpiczak plazmocytowy (MM, multiple myeloma) pozostaje nadal chorobą nieuleczalną. W ostatnich dwóch l...
Pentraxins – their importance in pathogenesis of systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is an autoimmune disease, whose main pathomechanism is attributed to the disturbed apoptotic process and dysfunction of the immune cells, leading to the accumulation of undegraded cellu...
Preliminary study on application of urine amino acids profiling for monitoring of renal tubular injury using GLC-MS
The early diagnosis of the nephrotoxic effect of xenobiotics and drugs is still an unsolved problem. Recent studies suggest a correlation between the nephrotoxic activity of xenobiotics and increased concentration of ami...